
Akers Biosciences, Inc. AKER
Akers Biosciences, Inc. Financial Ratios 2011-2026 | AKER
Annual Financial Ratios Akers Biosciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.0 | -0.2 | -0.6 | -0.2 | -1.0 | -0.3 | -2.6 | -2.7 | - | - |
P/S |
- | 0.6 | 3.8 | 0.3 | 1.1 | 1.5 | 1.8 | 1.2 | - | - |
EV/EBITDA |
-0.0 | -0.1 | -0.7 | -0.2 | -0.7 | -0.4 | -2.6 | -2.6 | - | - |
PEG |
-0.0 | -0.0 | -0.01 | 0.0 | -0.01 | 0.0 | -0.08 | -0.07 | - | - |
P/B |
0.0 | 0.1 | 1.1 | 0.1 | 1.0 | 0.5 | 0.5 | 1.0 | - | - |
P/CF |
-0.1 | -0.3 | -0.7 | -0.2 | -0.8 | -0.6 | -2.0 | -1.5 | - | - |
ROE % |
-50.84 | -41.56 | -185.97 | -63.70 | -97.52 | -141.02 | -21.12 | -37.04 | - | - |
ROA % |
-161.51 | -35.72 | -138.96 | -53.32 | -64.96 | -112.57 | -18.78 | -25.13 | - | - |
ROCE % |
-131.33 | -40.67 | -146.65 | -55.44 | -136.62 | -106.80 | -21.64 | -43.93 | - | - |
DSO |
- | 9.9 | 38.6 | 150.1 | 78.1 | 127.1 | 191.8 | 211.9 | - | - |
DIO |
- | 66.1 | 138.9 | 474.3 | 686.3 | 434.4 | 281.1 | 195.5 | - | - |
DPO |
- | 218.4 | 162.9 | 254.2 | 372.5 | 206.7 | 113.1 | 118.8 | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Akers Biosciences, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 20.38 | -0.8 % | $ 10.4 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 203.39 | -0.93 % | $ 58.5 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.67 | -2.84 % | $ 28.4 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.69 | -8.79 % | $ 175 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
LeMaitre Vascular
LMAT
|
$ 83.44 | -0.09 % | $ 1.87 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Merit Medical Systems
MMSI
|
$ 91.18 | -2.0 % | $ 5.31 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
$ 80.74 | -1.34 % | $ 40.4 B | ||
|
iRhythm Technologies
IRTC
|
$ 187.58 | 1.41 % | $ 5.85 B | ||
|
OraSure Technologies
OSUR
|
$ 2.5 | 0.6 % | $ 186 M | ||
|
AtriCure
ATRC
|
$ 41.29 | -0.36 % | $ 1.94 B | ||
|
Repro Med Systems
KRMD
|
$ 5.69 | 1.79 % | $ 259 M | ||
|
electroCore
ECOR
|
$ 4.81 | -1.26 % | $ 26.5 K | ||
|
ICU Medical
ICUI
|
$ 150.56 | -0.15 % | $ 3.67 B | ||
|
AngioDynamics
ANGO
|
$ 11.02 | -3.67 % | $ 450 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
$ 83.83 | -0.58 % | $ 16.7 B | ||
|
STERIS plc
STE
|
$ 259.25 | -0.25 % | $ 25.6 B | ||
|
Glaukos Corporation
GKOS
|
$ 113.49 | 0.99 % | $ 5.5 B | ||
|
Haemonetics Corporation
HAE
|
$ 83.15 | 0.48 % | $ 4.18 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.93 | 1.82 % | $ 184 M | ||
|
Nephros
NEPH
|
$ 5.28 | -2.4 % | $ 54.8 M | ||
|
Masimo Corporation
MASI
|
$ 137.22 | 0.45 % | $ 7.31 B | ||
|
Predictive Oncology
POAI
|
$ 6.37 | -0.78 % | $ 34.7 M | ||
|
Intuitive Surgical
ISRG
|
$ 592.66 | -0.03 % | $ 211 B | ||
|
Utah Medical Products
UTMD
|
$ 57.83 | 1.03 % | $ 210 M | ||
|
Microbot Medical
MBOT
|
$ 2.1 | -1.41 % | $ 21.4 M | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | -2.42 % | $ 22.3 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 22.84 | -1.64 % | $ 3.93 B | ||
|
Stereotaxis
STXS
|
$ 2.54 | -0.59 % | $ 205 M | ||
|
Pro-Dex
PDEX
|
$ 40.18 | -1.9 % | $ 132 M | ||
|
Pulse Biosciences
PLSE
|
$ 15.15 | 3.25 % | $ 728 M | ||
|
Repligen Corporation
RGEN
|
$ 168.5 | -2.18 % | $ 9.39 M | ||
|
ResMed
RMD
|
$ 248.48 | -0.28 % | $ 36.3 B | ||
|
BioLife Solutions
BLFS
|
$ 25.52 | -3.15 % | $ 1.18 B | ||
|
Retractable Technologies
RVP
|
$ 0.77 | 0.92 % | $ 23.1 M | ||
|
STAAR Surgical Company
STAA
|
$ 22.1 | -0.85 % | $ 1.09 B | ||
|
Teleflex Incorporated
TFX
|
$ 126.75 | 1.6 % | $ 5.94 B | ||
|
West Pharmaceutical Services
WST
|
$ 279.92 | -0.3 % | $ 20.4 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 12.38 | 0.04 % | $ 2.52 B |